Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM

Immuneering Corp

As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.
IMM-1-104 with mFFX generally well tolerated; 3 partial responders and 1 stable disease patient remain on treatment.
Raised net proceeds of $13.7M in January 2025 through at-the-market equity offering program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.